What is Nutraferma?
Nutraferma operates at the intersection of advanced microbiology and industrial agriculture. By leveraging patented solid-state fermentation technology, the company produces a sophisticated portfolio of direct-fed microbials, bio-active peptides, and yeast-based additives. Flagship products such as PepSoyGen and NF8 represent the company's commitment to enhancing animal health and feed efficiency. With production facilities strategically located in the United States and South Korea, Nutraferma maintains a robust supply chain capable of meeting the rigorous demands of the global feed ingredient industry, effectively bridging the gap between laboratory-scale innovation and large-scale commercial application.
How much funding has Nutraferma raised?
Nutraferma has raised a total of $163K across 1 funding round:
Debt
$163K
Debt (2021): $163K with participation from PPP
Key Investors in Nutraferma
PPP
Public-Private Partnership
What's next for Nutraferma?
The recent capital allocation is expected to catalyze Nutraferma's expansion into emerging markets while further optimizing its fermentation infrastructure. As the company transitions through this late-stage growth phase, management is likely to prioritize the commercialization of its next-generation phytogenic additives and the expansion of its intellectual property portfolio. By focusing on sustainable, high-performance feed solutions, Nutraferma is well-positioned to capture additional market share, addressing the growing global demand for efficient, bio-based animal nutrition. Future strategic initiatives will likely involve deepening research partnerships and enhancing production capacity to maintain its competitive edge in the biotech-driven agricultural sector.
See full Nutraferma company page
